Skip to main content

Table 2 The association between tumor mutation burden (TMB) of neuroendocrine pathways and breast cancer prognosis

From: Neuroendocrine pathways and breast cancer progression: a pooled analysis of somatic mutations and gene expression from two large breast cancer cohorts

Pathway

Somatic Mutation a

WCH + TCGA

WCH

TCGA

P for heterogeneity

Cases

Controls

Odds ratio b

Cases

Controls

Odds ratio

Cases

Controls

Odds ratios

Adrenergic

No mutation

77

75

Ref

38

49

Ref

39

26

Ref

-

Any mutation

131

133

1.16 (0.74, 1.81)

58

47

2.01 (1.06, 3.8)

73

86

0.66 (0.34, 1.29)

0.02

TMB

208

208

1.07 (0.91, 1.24)

96

96

1.28 (1.02, 1.59)

112

112

0.89 (0.7, 1.12)

0.03

Glucocorticoid

No mutation

122

137

Ref

55

65

Ref

67

82

Ref

-

Any Mutation

86

71

1.66 (1.07, 2.58)

41

31

1.81 (0.95, 3.44)

45

40

1.57 (0.84, 2.95)

0.76

TMB

208

208

1.17 (1.02, 1.35)

96

96

1.22 (0.99, 1.51)

112

112

1.12 (0.91, 1.38)

0.57

Dopaminergic

No mutation

135

138

Ref

59

68

Ref

76

70

Ref

-

Any Mutation

73

70

1.07 (0.69, 1.66)

37

28

1.84 (0.95, 3.56)

36

42

0.7 (0.37, 1.33)

0.04

TMB

208

208

1.02 (0.89, 1.17)

96

96

1.2 (0.98, 1.46)

112

112

0.88 (0.72, 1.08)

0.03

Serotonergic

No mutation

135

140

Ref

60

70

Ref

75

70

Ref

-

Any Mutation

73

68

1.04 (0.66, 1.62)

36

26

1.74 (0.9, 3.36)

37

42

0.61 (0.32, 1.18)

0.03

TMB

208

208

1.02 (0.89, 1.18)

96

96

1.2 (0.98, 1.47)

112

112

0.85 (0.68, 1.05)

0.02

Cholinergic

No mutation

61

76

Ref

30

49

Ref

21

27

Ref

-

Any Mutation

147

132

1.59 (1.01, 2.53)

66

47

2.75 (1.42, 5.32)

81

85

0.87 (0.44, 1.72)

0.02

TMB

208

208

1.14 (0.97, 1.34)

96

96

1.33 (1.06, 1.67)

112

112

0.95 (0.74, 1.21)

0.05

  1. aSomatic mutation burden of candidate genes in each pathway were firstly categorized as mutated or nonmutated, and then treated as a continuous variable (log2 scale)
  2. bOdds ratios were estimated using logistic regression models and adjusted for cohort membership, age at diagnosis, menopausal status at diagnosis, molecular subtype, and cancer stage
  3. cBetween-cohort heterogeneity was calculated using Q-statistics